171 related articles for article (PubMed ID: 22963984)
21. Anti-modified LDL antibodies and LDL-containing immune complexes in IDDM patients and healthy controls.
Mironova M; Virella G; Virella-Lowell I; Lopes-Virella MF
Clin Immunol Immunopathol; 1997 Oct; 85(1):73-82. PubMed ID: 9325072
[TBL] [Abstract][Full Text] [Related]
22. The Pathogenic Role of the Adaptive Immune Response to Modified LDL in Diabetes.
Virella G; Lopes-Virella MF
Front Endocrinol (Lausanne); 2012; 3():76. PubMed ID: 22715334
[TBL] [Abstract][Full Text] [Related]
23. Serum malondialdehyde-modified low-density lipoprotein levels on admission predict prognosis in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Amioka N; Miyoshi T; Otsuka H; Yamada D; Takaishi A; Ueeda M; Hirohata S; Ito H
J Cardiol; 2019 Sep; 74(3):258-266. PubMed ID: 30898480
[TBL] [Abstract][Full Text] [Related]
24. Soluble form of receptor for advanced glycation end products and incidence of new cardiovascular events among patients with cardiovascular disease.
Reichert S; Triebert U; Santos AN; Hofmann B; Schaller HG; Schlitt A; Schulz S
Atherosclerosis; 2017 Nov; 266():234-239. PubMed ID: 28864204
[TBL] [Abstract][Full Text] [Related]
25. Autoantibodies against oxidized LDL do not predict atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus.
Uusitupa MI; Niskanen L; Luoma J; Vilja P; Mercuri M; Rauramaa R; Ylä-Herttuala S
Arterioscler Thromb Vasc Biol; 1996 Oct; 16(10):1236-42. PubMed ID: 8857919
[TBL] [Abstract][Full Text] [Related]
26. Definition of the immunogenic forms of modified human LDL recognized by human autoantibodies and by rabbit hyperimmune antibodies.
Virella G; Thorpe SR; Alderson NL; Derrick MB; Chassereau C; Rhett JM; Lopes-Virella MF
J Lipid Res; 2004 Oct; 45(10):1859-67. PubMed ID: 15258197
[TBL] [Abstract][Full Text] [Related]
27. Soluble LDL-immune complexes in type 2 diabetes and vascular disease.
Turk Z; Sesto M; Skodlar J; Ferencak G; Turk N; Stavljenić-Rukavina A
Horm Metab Res; 2002 Apr; 34(4):196-201. PubMed ID: 11987029
[TBL] [Abstract][Full Text] [Related]
28. Relationship between oxidized LDL, IgM, and IgG autoantibodies to ox-LDL levels with recurrent cardiovascular events in Swedish patients with previous myocardial infarction.
Crisby M; Henareh L; Agewall S
Angiology; 2014 Nov; 65(10):932-6. PubMed ID: 24288363
[TBL] [Abstract][Full Text] [Related]
29. Circulating malondialdehyde-modified low-density lipoprotein (MDA-LDL) as a novel predictor of clinical outcome after endovascular therapy in patients with peripheral artery disease (PAD).
Takamura TA; Tsuchiya T; Oda M; Watanabe M; Saito R; Sato-Ishida R; Akao H; Kawai Y; Kitayama M; Kajinami K
Atherosclerosis; 2017 Aug; 263():192-197. PubMed ID: 28651186
[TBL] [Abstract][Full Text] [Related]
30. OxPL/apoB, lipoprotein(a) and OxLDL biomarkers and cardiovascular disease in chronic hemodialysis patients.
Bossola M; Tazza L; Luciani G; Tortorelli A; Tsimikas S
J Nephrol; 2011; 24(5):581-8. PubMed ID: 21404224
[TBL] [Abstract][Full Text] [Related]
31. Increased levels of autoantibodies against copper-oxidized low density lipoprotein, malondialdehyde-modified low density lipoprotein and cardiolipin in patients with rheumatoid arthritis.
Cvetkovic JT; Wållberg-Jonsson S; Ahmed E; Rantapää-Dahlqvist S; Lefvert AK
Rheumatology (Oxford); 2002 Sep; 41(9):988-95. PubMed ID: 12209031
[TBL] [Abstract][Full Text] [Related]
32. Autoantibodies against oxidized low-density lipoprotein and C-reactive protein are associated with diabetes and myocardial infarction in women.
Dotevall A; Hulthe J; Rosengren A; Wiklund O; Wilhelmsen L
Clin Sci (Lond); 2001 Nov; 101(5):523-31. PubMed ID: 11672458
[TBL] [Abstract][Full Text] [Related]
33. Development of capture assays for different modifications of human low-density lipoprotein.
Virella G; Derrick MB; Pate V; Chassereau C; Thorpe SR; Lopes-Virella MF
Clin Diagn Lab Immunol; 2005 Jan; 12(1):68-75. PubMed ID: 15642987
[TBL] [Abstract][Full Text] [Related]
34. Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events.
Tsimikas S; Willeit P; Willeit J; Santer P; Mayr M; Xu Q; Mayr A; Witztum JL; Kiechl S
J Am Coll Cardiol; 2012 Nov; 60(21):2218-29. PubMed ID: 23122790
[TBL] [Abstract][Full Text] [Related]
35. Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction.
Wu R; Nityanand S; Berglund L; Lithell H; Holm G; Lefvert AK
Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):3159-63. PubMed ID: 9409306
[TBL] [Abstract][Full Text] [Related]
36. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial.
Tsimikas S; Witztum JL; Miller ER; Sasiela WJ; Szarek M; Olsson AG; Schwartz GG;
Circulation; 2004 Sep; 110(11):1406-12. PubMed ID: 15353498
[TBL] [Abstract][Full Text] [Related]
37. Detection of autoantibodies against oxidized low-density lipoproteins and of IgG-bound low density lipoproteins in patients with coronary artery disease.
Boullier A; Hamon M; Walters-Laporte E; Martin-Nizart F; Mackereel R; Fruchart JC; Bertrand M; Duriez P
Clin Chim Acta; 1995 Jun; 238(1):1-10. PubMed ID: 7554289
[TBL] [Abstract][Full Text] [Related]
38. Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events.
Tsimikas S; Brilakis ES; Lennon RJ; Miller ER; Witztum JL; McConnell JP; Kornman KS; Berger PB
J Lipid Res; 2007 Feb; 48(2):425-33. PubMed ID: 17093289
[TBL] [Abstract][Full Text] [Related]
39. Anti-modified LDL antibodies, LDL-containing immune complexes, and susceptibility of LDL to in vitro oxidation in patients with type 2 diabetes.
Mironova MA; Klein RL; Virella GT; Lopes-Virella MF
Diabetes; 2000 Jun; 49(6):1033-41. PubMed ID: 10866057
[TBL] [Abstract][Full Text] [Related]
40. Absence of relationship between plasma Lp(a), Lp-AI, anti-oxidized LDL autoantibodies, LDL immune complexes concentrations and restenosis after percutaneous transluminal coronary angioplasty.
Boullier A; Walters-Laporte E; Hamon M; Tailleux A; Amant C; Amouyel P; Fruchart J; Bertrand M; Duriez P
Clin Chim Acta; 2000 Sep; 299(1-2):129-40. PubMed ID: 10900299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
